ArticleJournal of bone oncology2022

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.

Makoto Nakagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.